Victory Square Provides Corporate Update on Healthcare Infrastructure Strategy and Portfolio Developments

Executive Summary

• Victory Square Technologies outlines its 2026 strategic focus on scaling healthcare infrastructure across digital health, biotech, pet health, diagnostics, and immersive tech platforms.
• Hydreight Technologies (major subsidiary) provides FY 2026 revenue guidance of ~US$150 million with Q1 2026 revenue expected between US$25‑28 million and an Adjusted EBITDA margin of 15‑17%.
• The company highlights progress on its $10 M Digital Health Accelerator, Insu Therapeutics’ pre‑clinical buccal semaglutide program, Pawsible Ventures’ new pet‑health fund and incubator, SafeTest’s point‑of‑care diagnostics in Brazil, and XR Immersive Technologies’ plan to resume trading.

Key Details

• Strategic Focus: Build regulated, multi‑state healthcare infrastructure (physician networks, pharmacy enablement, telehealth rails, compliance frameworks).
• Digital Health Accelerator: $10 M fund launched Jan 2025 with Hydreight; targets U.S. operators ≥US$750k annual revenue for national scaling via VSDHOne platform.
• Hydreight FY 2026 Guidance:
• Revenue ≈ US$150 million (full year).
• Q1 2026 revenue forecast: US$25‑28 million.
• Adjusted EBITDA margin target: 15‑17%.
• Insu Therapeutics: Completed pre‑clinical buccal semaglutide study; received UBC Research Ethics Board approval to begin advanced animal studies for its oral peptide delivery platform.
• Pawsible Ventures (Pet Health): Launched a $10 M venture fund, venture studio model, and inaugural incubator program beginning Mar 2026; investor webinar scheduled Feb 19, 2026.
• SafeTest Diagnósticos (Brazil): Advancing point‑of‑care cervical cancer test (lateral flow) and HTLV diagnostic; aims to expand access in urban/rural markets.
• XR Immersive Technologies: Working toward lifting Cease Trade Order; progressing debt restructuring to improve balance sheet flexibility.
• Hydreight Share Option Exercise: Third parties exercised options for 1,472,222 Hydreight common shares – administrative, no change to portfolio strategy.
• Forward‑Looking Statements: Include revenue guidance, platform expansion expectations, clinical timelines, potential spin‑outs, NAV estimates, and debt restructuring plans; subject to risks outlined in the release.

Notable Quotes

“Our strategy extends beyond any one product. We are building the operational and regulatory infrastructure required to operate effectively in a complex healthcare landscape.” – Shafin Diamond Tejani, Chairman & CEO, Victory Square Technologies Inc.